AT 1015

Known as: AT-1015 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2004
012320002004

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
OBJECTIVE The effect of AT-1015, a serotonin(2A) receptor antagonist, on the resaturation of ischemic muscle in a… (More)
Is this relevant?
Review
2004
Review
2004
AT-1015 is a novel selective 5-HT2A serotonin receptor antagonist that is known to impair platelet aggregation and… (More)
Is this relevant?
2004
2004
OBJECTIVE To assess the safety of AT-1015 in combination with high-dose aspirin (300 mg daily). Study subjects were 17 healthy… (More)
Is this relevant?
2003
2003
The purpose of this study was to examine the inhibitory effects of AT-1015, a newly synthesized 5-HT(2) receptor antagonist, on… (More)
Is this relevant?
2002
2002
The purpose of this study was to investigate the association and dissociation kinetics of [3H]AT-1015 from 5-HT2 receptors in… (More)
Is this relevant?
2001
2001
The antithrombotic activity of N-[2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidino)ethyl]-1-formyl-4-piperidinecarboxamide… (More)
Is this relevant?
2001
2001
This study investigated the binding affinities of a newly synthesized 5-HT2 antagonist, AT-1015 (N-[2-[4-(5H-dibenzo[a,d… (More)
Is this relevant?
2001
2001
The object of this study was to investigate the binding affinity of a newly synthesized 5-HT2 antagonist, (N-[2-[4-(5H-dibenzo[a… (More)
  • table 1
  • table 2
Is this relevant?
2000
2000
The serotonin (5-HT2A) antagonistic activities and the protective effect on laurate-induced peripheral vascular lesions of AT… (More)
Is this relevant?
2000
2000
Inhibitory effects of a newly synthesized 5-HT2 receptor antagonist, AT-1015 (N-[2-[4-(5H-dibenzo[a,d]cyclohepten-5-ylidene… (More)
Is this relevant?